{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.6590","value":"2.0947"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"}],"units":"Participants"}],"description":"Time to response was measured from first day of treatment to the first date of documented response.","dispersionType":"Standard Deviation","groups":[{"description":"Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.","id":"OG000","title":"Pralatrexate"}],"paramType":"MEAN","populationDescription":"The secondary analyses was performed using the safety population and repeated using the per-protocol population.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Time to Response (TTR)","type":"SECONDARY","unitOfMeasure":"months"}